ModeX Therapeutics, Inc.

Biopharma Acquisitions Biopharma merger and acquisition value for the second quarter of 2022 reached $25.4bn from 36 transactions, 20 of which had disclosed values. Four M&A transactions hit or exceed

Public health and biopharma leaders at a recent summit highlighted areas that need attention to be better prepared to tackle the next pandemic and also some key lessons learned as the world struggles